ketorolac has been researched along with Meniscitis in 1 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dogan, N | 1 |
| Erdem, AF | 1 |
| Gundogdu, C | 1 |
| Kursad, H | 1 |
| Kizilkaya, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of Corticosteroid vs Ketorolac Shoulder Injections: a Prospective Double-Blinded Randomized Trial[NCT04895280] | Phase 4 | 400 participants (Anticipated) | Interventional | 2024-04-30 | Not yet recruiting | ||
| Effectiveness of Corticosteroid vs. Ketorolac Shoulder Injections: A Prospective Double-Blinded Randomized Trial[NCT04115644] | Phase 4 | 82 participants (Actual) | Interventional | 2017-05-01 | Terminated (stopped due to Covid-19 and we failed to submit annual report for 2017 and 2018) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Pain as measured by the Visual Analog Scale after first injection. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Baseline - immediately after the injection
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.197 |
| Group 2 (Ketorolac) | 3.577 |
| Group 3 (Kenalog) | 3.677 |
Pain as measured by the Visual Analog Scale prior to first injection. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Baseline - pre-injection
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 5.77 |
| Group 2 (Ketorolac) | 4.57 |
| Group 3 (Kenalog) | 4.67 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Day 2
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 2.347 |
| Group 2 (Ketorolac) | 2.837 |
| Group 3 (Kenalog) | 2.67 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 1
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.397 |
| Group 2 (Ketorolac) | 3.7 |
| Group 3 (Kenalog) | 3.257 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 12
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.447 |
| Group 2 (Ketorolac) | 1.417 |
| Group 3 (Kenalog) | 2.027 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 2
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.547 |
| Group 2 (Ketorolac) | 2.67 |
| Group 3 (Kenalog) | 2.57 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 4
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.547 |
| Group 2 (Ketorolac) | 2.67 |
| Group 3 (Kenalog) | 2.317 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 6
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.357 |
| Group 2 (Ketorolac) | 2.757 |
| Group 3 (Kenalog) | 2.687 |
1 other study available for ketorolac and Meniscitis
| Article | Year |
|---|---|
The effects of ketorolac and morphine on articular cartilage and synovium in the rabbit knee joint.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Inflamma | 2004 |
The effects of ketorolac and morphine on articular cartilage and synovium in the rabbit knee joint.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Inflamma | 2004 |
The effects of ketorolac and morphine on articular cartilage and synovium in the rabbit knee joint.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Inflamma | 2004 |
The effects of ketorolac and morphine on articular cartilage and synovium in the rabbit knee joint.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Inflamma | 2004 |